The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of Hepatocellular Carcinoma in Cirrhotic Patients

Sohag University

Status: Not yet enrolling

Conditions: Hepatocellular Carcinoma

Treatments: Other: measure of Glutamine synthetase and BCLFAF1

Study type: Observational

Funder types: Other

Identifiers

NCT06328283

Soh-Med-24-02-01MD

Details and patient eligibility

About

Hepatocellular carcinoma (HCC) is the most prominent kind of liver cancer, accounting for 85% of primary liver malignancies. It is a very aggressive tumor, having a terrible prognosis and poor survival rate HCC is ranked as the sixth most common type of cancer and the third leading cause of cancer-related mortalities world wide.

HCC incidences arise in complications associated with chronic liver disease like cirrhosis, endemic hepatitis B virus (HBV)/hepatitis C virus (HCV) infections, non alcoholic fatty liver disease (NAFLD), and alcohol-related liver disease (Torre, 2015).

Enrollment: 90 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• A total 90 adult patients with liver cirrhosis attending the outpatient clinic or in patient section of the department of tropical medicine and gastroenterology at Sohag University Hospital will be included in the study. Patients will be divided into two groups:

Group I:

The study group will include 45 patients diagnosed with liver cirrhosis with absence of hepatic focal lesion as control group. Cirrhosis will be determined according to clinical , sereological ,radiological findings.

Group II:

The study group will include 45 patient with HCC on top of liver cirrhosis .All causes of liver cirrhosis will be accepted .HCC will be assessed by triphasic CT or MRI or histological validation .In these group we will take patients with liver cirrhosis with early hepatocellular carcinoma that defined as tumors smaller than 3cm and three or fewer in number at stage A according to BCLC staging also sometimes it includes solitary tumors up to 5 cm in size as defined in the Milan criteria. Both very early and early stage tumors are relatively small but both are hyper vascular in arterial phase.

Exclusion criteria

1. Non cirrhotic patients.
2. Patients with distant metastasis.
3. Patients aged below18 years.
4. Patients with other malignancy rather than HCC.
5. Patients with late stage of HCC.

Trial design

90 participants in 2 patient groups

cases group

Description:

cirrhotic patients with early hepatocellular carcinoma

Treatment:

Other: measure of Glutamine synthetase and BCLFAF1

control group

Description:

cirrhotic patients with no hepatocellular carcinoma

Treatment:

Other: measure of Glutamine synthetase and BCLFAF1